60 DEGREES PHARMACEUTICALS INC C/WTS (TO PUR COM) News

Express News | 60 Degrees Pharma Announces Irb Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients With Persistent Babesia Microti Despite Prior Treatment

ReutersJul 9 06:31 ET

Express News | First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

ReutersJun 27 07:59 ET

Express News | 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis

ReutersJun 11 07:59 ET

Express News | Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

ReutersMay 30 07:59 ET

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024.

GlobeNewswireMay 15 13:45 ET

10-Q: Quarterly report

SEC announcementMay 15 12:00 ET · Announcements

Express News | 60 Degrees Pharmaceuticals Inc - Enrollment for Babesiosis Trial Set for Summer 2024

ReutersMay 8 07:59 ET

Express News | 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

ReutersMay 8 07:59 ET

Express News | 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

ReutersMay 2 07:59 ET

60 Degrees Pharmaceuticals Announces Communication From the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP, SXTPW) today announced that the U.S. Food and Drug Administration (FDA) has communicated its intention to send any comments regarding the Company's babesiosis trial within the month of April, 2024, rather than March, 2024 as anticipated by the Company.

GlobeNewswireMar 14 07:59 ET

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharmaceuticals" or the "Company"), specialists in developing and marketing new medicines for the

GlobeNewswireJan 31 11:15 ET

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Globe NewswireJan 30 09:00 ET

60 Degrees Pharma Plans Pivotal Babesiosis Study With Tafenoquine Following Jan 17 FDA Meeting

In advance of the meeting, 60P provided to the FDA an information package that included a presentation of the unmet medical need for a new therapeutic for hospitalized babesiosis patients.

GlobeNewswireJan 22 07:59 ET

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60P Australia Pty Ltd, will not re-submit its investigational new drug application ("IND") for ACLR8-LR, a Phase IIB study of tafenoquine compared to placebo in patients with mild to moderate COVID-19 disease and low risk of disease progression.

GlobeNewswireOct 12, 2023 16:16 ET

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

60 Degrees Pharmaceuticals, Inc. ("60P") (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that 60P Australia Pty Ltd, a majority-owned subsidiary of 60P, has withdrawn its investigational new drug (IND) application for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19, and intends to submit a new IND in the fourth quarter.

GlobeNewswireSep 18, 2023 16:16 ET

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Management investor presentation webcast available Monday 9/11, 7:00 AM ETAttendees may request 1 x 1 meetings with management at meetings@hcwco.comWASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60

GlobeNewswireSep 6, 2023 07:31 ET

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

60 Degrees Pharmaceuticals Inc. (Nasdaq: SXTP) today announced that the Canadian Intellectual Property Office (CIPO) has issued the Company a patent covering the use of novel regimens of tafenoquine for the prevention of malaria in malaria-naive individuals.

GlobeNewswireJul 31, 2023 07:59 ET

60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering

Globe NewswireJul 14, 2023 12:39 ET

60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering

WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious disea

GlobeNewswireJul 12, 2023 12:29 ET